In this regard, our panel design covers genes that have been related to such mechanisms of resistance, as MAP2K1, MAP2K2, MITF, PTEN, PIK3CA, NF1, RAC1 and HOXD8. Therefore, application of this melanoma-specific panel could be of interest in the management of metastatic patients, not only for the detection of actionable mutations, but also to identify those patients who may more likely benefit from those treatments. The gene discussed is NF1; the disease is melanoma.